Radiology and Oncology (Jul 2020)

[18F]FDG PET immunotherapy radiomics signature (iRADIOMICS) predicts response of non-small-cell lung cancer patients treated with pembrolizumab

  • Valentinuzzi Damijan,
  • Vrankar Martina,
  • Boc Nina,
  • Ahac Valentina,
  • Zupancic Ziga,
  • Unk Mojca,
  • Skalic Katja,
  • Zagar Ivana,
  • Studen Andrej,
  • Simoncic Urban,
  • Eickhoff Jens,
  • Jeraj Robert

DOI
https://doi.org/10.2478/raon-2020-0042
Journal volume & issue
Vol. 54, no. 3
pp. 285 – 294

Abstract

Read online

Immune checkpoint inhibitors have changed the paradigm of cancer treatment; however, non-invasive biomarkers of response are still needed to identify candidates for non-responders. We aimed to investigate whether immunotherapy [18F]FDG PET radiomics signature (iRADIOMICS) predicts response of metastatic non-small-cell lung cancer (NSCLC) patients to pembrolizumab better than the current clinical standards.

Keywords